Jørgensen, Anna Kirstine;
Ong, Jun Jie;
Parhizkar, Maryam;
Goyanes, Alvaro;
Basit, Abdul W;
(2023)
Advancing non-destructive analysis of 3D printed medicines.
Trends in Pharmacological Sciences
S0165.
10.1016/j.tips.2023.03.006.
(In press).
Preview |
PDF
1-s2.0-S0165614723000664-main.pdf - Published Version Download (2MB) | Preview |
Abstract
Pharmaceutical 3D printing (3DP) has attracted significant interest over the past decade for its ability to produce personalised medicines on demand. However, current quality control (QC) requirements for traditional large-scale pharmaceutical manufacturing are irreconcilable with the production offered by 3DP. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) have recently published documents supporting the implementation of 3DP for point-of-care (PoC) manufacturing along with regulatory hurdles. The importance of process analytical technology (PAT) and non-destructive analytical tools in translating pharmaceutical 3DP has experienced a surge in recognition. This review seeks to highlight the most recent research on non-destructive pharmaceutical 3DP analysis, while also proposing plausible QC systems that complement the pharmaceutical 3DP workflow. In closing, outstanding challenges in integrating these analytical tools into pharmaceutical 3DP workflows are discussed.
| Type: | Article |
|---|---|
| Title: | Advancing non-destructive analysis of 3D printed medicines |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.tips.2023.03.006 |
| Publisher version: | https://doi.org/10.1016/j.tips.2023.03.006 |
| Language: | English |
| Additional information: | © 2023 The Author(s). Published by Elsevier Ltd. under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | additive manufacturing of drug products, digital health and therapeutics, future fabrication of pharmaceuticals, industry 4.0, non-destructive quality control of drug formulations, point of care manufacture and analysis of personalised medications |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10169202 |
Archive Staff Only
 |
View Item |
